These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 11411816)

  • 1. The apparent effects of ziprasidone on plasma lipids and glucose.
    Kingsbury SJ; Fayek M; Trufasiu D; Zada J; Simpson GM
    J Clin Psychiatry; 2001 May; 62(5):347-9. PubMed ID: 11411816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in weight, plasma lipids, and glucose in adults treated with ziprasidone: a comprehensive analysis of pfizer-initiated clinical trials.
    Pappadopulos E; Newcomer JW; Kolluri S
    J Clin Psychiatry; 2012 Jun; 73(6):e742-8. PubMed ID: 22795213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ziprasidone's effect on metabolic markers in patients with diabetes and chronic schizophrenia.
    Lindenmayer JP; Tedeschi F; Yusim A; Khan A; Kaushik S; Smith RC; Parakadavil M
    Clin Schizophr Relat Psychoses; 2012 Jan; 5(4):185-92. PubMed ID: 22182455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term metabolic effects of aripiprazole, ziprasidone and quetiapine: a pragmatic clinical trial in drug-naïve patients with a first-episode of non-affective psychosis.
    Vázquez-Bourgon J; Pérez-Iglesias R; Ortiz-García de la Foz V; Suárez Pinilla P; Díaz Martínez Á; Crespo-Facorro B
    Psychopharmacology (Berl); 2018 Jan; 235(1):245-255. PubMed ID: 29075885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness, tolerability, and safety of ziprasidone in patients with schizophrenia or schizoaffective disorder: results of a multi-centre observational trial.
    Kudla D; Lambert M; Domin S; Kasper S; Naber D
    Eur Psychiatry; 2007 Apr; 22(3):195-202. PubMed ID: 17140769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weight, lipids, glucose, and behavioral measures with ziprasidone treatment in a population with mental retardation.
    Cohen S; Fitzgerald B; Okos A; Khan S; Khan A
    J Clin Psychiatry; 2003 Jan; 64(1):60-2. PubMed ID: 12590625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder.
    Potkin SG; Ogasa M; Cucchiaro J; Loebel A
    Schizophr Res; 2011 Nov; 132(2-3):101-7. PubMed ID: 21889878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone.
    Weiden PJ; Newcomer JW; Loebel AD; Yang R; Lebovitz HE
    Neuropsychopharmacology; 2008 Apr; 33(5):985-94. PubMed ID: 17637612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study.
    Sacchetti E; Galluzzo A; Valsecchi P; Romeo F; Gorini B; Warrington L;
    Schizophr Res; 2009 May; 110(1-3):80-9. PubMed ID: 19269791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early changes of plasma lipids during treatment with atypical antipsychotics.
    Rettenbacher MA; Ebenbichler C; Hofer A; Kemmler G; Baumgartner S; Edlinger M; Hummer M; Lechleitner M; Fleischhacker WW
    Int Clin Psychopharmacol; 2006 Nov; 21(6):369-72. PubMed ID: 17012984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study.
    Sacchetti E; Galluzzo A; Valsecchi P; Romeo F; Gorini B; Warrington L;
    Schizophr Res; 2009 Aug; 113(1):112-21. PubMed ID: 19606529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement in antipsychotic-related metabolic disturbances in patients with schizophrenia switched to ziprasidone.
    Montes JM; Rodriguez JL; Balbo E; Sopelana P; Martin E; Soto JA; Delgado JF; Diez T; Villardaga I
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):383-8. PubMed ID: 17129654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A twenty-four-week, open-label study on ziprasidone's efficacy and influence on glucolipid metabolism in patients with schizophrenia and metabolic disorder.
    Li CH; Shi L; Zhan GL; Rao SZ; Zhang H
    Eur Rev Med Pharmacol Sci; 2013 Aug; 17(16):2136-40. PubMed ID: 23893178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
    Simpson GM; Glick ID; Weiden PJ; Romano SJ; Siu CO
    Am J Psychiatry; 2004 Oct; 161(10):1837-47. PubMed ID: 15465981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia.
    Breier A; Berg PH; Thakore JH; Naber D; Gattaz WF; Cavazzoni P; Walker DJ; Roychowdhury SM; Kane JM
    Am J Psychiatry; 2005 Oct; 162(10):1879-87. PubMed ID: 16199834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjunctive effects of aripiprazole on metabolic profiles: comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs.
    Wang LJ; Ree SC; Huang YS; Hsiao CC; Chen CK
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jan; 40():260-6. PubMed ID: 23085073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching to ziprasidone in the clinical practice setting: an open-label study.
    Gutiérrez Fraile M; de la Gándara Martín JJ; Bobes García J
    Int J Psychiatry Med; 2013; 45(2):125-42. PubMed ID: 23977817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ziprasidone as an adjuvant for clozapine- or olanzapine-associated medical morbidity in chronic schizophrenia.
    Henderson DC; Fan X; Copeland PM; Sharma B; Borba CP; Forstbauer SI; Miley K; Boxill R; Freudenreich O; Cather C; Evins AE; Goff DC
    Hum Psychopharmacol; 2009 Apr; 24(3):225-32. PubMed ID: 19283774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spotlight on ziprasidone in schizophrenia and schizoaffective disorder.
    Gunasekara NS; Spencer CM; Keating GM
    CNS Drugs; 2002; 16(9):645-52. PubMed ID: 12153335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of ziprasidone on metabolic syndrome risk factors in subjects with schizophrenia: a 1 year, open-label, prospective study.
    Chue P; Mandel FS; Therrien F
    Curr Med Res Opin; 2014 Jun; 30(6):997-1005. PubMed ID: 24568177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.